357 related articles for article (PubMed ID: 23737503)
1. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
Yang H; Chennamaneni LR; Ho MWT; Ang SH; Tan ESW; Jeyaraj DA; Yeap YS; Liu B; Ong EH; Joy JK; Wee JLK; Kwek P; Retna P; Dinie N; Nguyen TTH; Tai SJ; Manoharan V; Pendharkar V; Low CB; Chew YS; Vuddagiri S; Sangthongpitag K; Choong ML; Lee MA; Kannan S; Verma CS; Poulsen A; Lim S; Chuah C; Ong TS; Hill J; Matter A; Nacro K
J Med Chem; 2018 May; 61(10):4348-4369. PubMed ID: 29683667
[TBL] [Abstract][Full Text] [Related]
3. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Cherian J; Nacro K; Poh ZY; Guo S; Jeyaraj DA; Wong YX; Ho M; Yang HY; Joy JK; Kwek ZP; Liu B; Wee JL; Ong EH; Choong ML; Poulsen A; Lee MA; Pendharkar V; Ding LJ; Manoharan V; Chew YS; Sangthongpitag K; Lim S; Ong ST; Hill J; Keller TH
J Med Chem; 2016 Apr; 59(7):3063-78. PubMed ID: 27011159
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting MNK Selectively Targets Cervical Cancer via Suppressing eIF4E-Mediated β-Catenin Activation.
Zhang W; Su X; Li S; Wang Y; Wang Q; Zeng H
Am J Med Sci; 2019 Sep; 358(3):227-234. PubMed ID: 31327462
[TBL] [Abstract][Full Text] [Related]
7. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
10. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
11. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
12. The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma.
Seidel P; Sun Q; Costa L; Lardinois D; Tamm M; Roth M
Cell Signal; 2016 Oct; 28(10):1555-62. PubMed ID: 27418099
[TBL] [Abstract][Full Text] [Related]
13. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
14. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
15. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Abrahamsson AE; Geron I; Gotlib J; Dao KH; Barroga CF; Newton IG; Giles FJ; Durocher J; Creusot RS; Karimi M; Jones C; Zehnder JL; Keating A; Negrin RS; Weissman IL; Jamieson CH
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3925-9. PubMed ID: 19237556
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
18. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.
Wheater MJ; Johnson PW; Blaydes JP
Cancer Biol Ther; 2010 Oct; 10(7):728-35. PubMed ID: 20686366
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]